While the number of COVID-19 cases continues to surge, there is positive news on the vaccine front. In early clinical trial data, two vaccines have now shown at least 90% effectiveness in reducing the risk of infection from the virus that causes COVID-19. While more time and research is needed to understand how long the immunity from a vaccine lasts, experts believe a vaccine could be approved for emergency use authorization before the end of the year.
On the Mayo Clinic Q&A podcast, Dr. Gregory Poland, an infectious diseases expert and head of Mayo Clinic's Vaccine Research Group, discusses the latest on current COVID-19 clinical trials. Dr. Poland also explains what public health experts mean by community spread of the virus and why that leads to exponential growth in cases of COVID-19.
Information in this post was accurate at the time of its posting. Due to the fluid nature of the COVID-19 pandemic, scientific understanding along with guidelines and recommendations may have changed since the original publication date. For more information and all your COVID-19 coverage, go to the Mayo Clinic News Network: [ Ссылка ]
For the safety of our patients, staff and visitors, Mayo Clinic has strict masking policies in place. Anyone shown without a mask was either recorded prior to COVID-19 or recorded in a non-patient care area where social distancing and other safety protocols were followed.
Dr. Poland has served as a consultant for Merck & Co. Inc., Medicago Inc., GlaxoSmithKline plc, Sanofi Pasteur, Emergent BioSolutions Inc., Dynavax Technologies Corp., Genentech Inc., Eli Lilly and Co., Kentucky BioProcessing Inc. and Genevant Sciences Corp., and Janssen Pharmaceuticals Inc. He is a paid scientific adviser for Johnson & Johnson. Honoraria: Elsevier.
